-+ 0.00%
-+ 0.00%
-+ 0.00%

PROMIS NEUROSCIENCES ANNOUNCES NEW PEER-REVIEWED PUBLICATION SHOWING PLASMA PTAU AS A PREDICTIVE EARLY ENDPOINT IN ALZHEIMER’S TRIALS, SUPPORTING ITS ONGOING PHASE 1B PRECISE-AD TRIAL WITH PMN310

Reuters·12/01/2025 12:30:01

Please log in to view news